Abiraterone

Also known as: Abiraterone Acetate

Active ingredient description

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L02BX03
Abiraterone
L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX03

Medicines

Abiraterone is the active ingredient of these drugs:

Drug
Countries
ABIRANAT

Hong Kong Singapore

BALEFIO

Brazil

MATIZ

Brazil

RARIJA

Brazil

TATICA

Lithuania

VENOMY

Brazil

YONSA

United States

ZOSTIDE

Brazil

ZYTIGA

Australia Austria Brazil Canada Cyprus

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
ZYTIGA Tablet
Summary of product characteristics (SPC)
ZYTIGA Film-coated tablet
Summary of product characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

G819A456D0 - ABIRATERONE

CAS registry number

154229-19-3 - abiraterone

SNOMED-CT

699678007 - Abiraterone (substance)

Next: Usage